

Terry A Jacobson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7145899/terry-a-jacobson-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

178
papers

14,573
citations

63
h-index

119
g-index

185
ext. papers

17,172
ext. citations

5.1
avg, IF

6.88
L-index

#	Paper	IF	Citations
178	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment.. <i>JAMA Network Open</i> , 2022 , 5, e2148172	10.4	1
177	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.. <i>Journal of the American Heart Association</i> , 2022 , e022937	6	3
176	Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024999	6	0
175	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1660-1671	15.1	7
174	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1525-1537	15.1	6
173	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2021 , 144, 1845-1855	16.7	10
172	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. <i>Circulation</i> , 2021 , 144, 1750-1759	16.7	8
171	Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. <i>Circulation</i> , 2021 , 143, 33-44	16.7	25
170	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e61-e63	6.4	9
169	The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. <i>Journal of Clinical Lipidology</i> , 2021 , 15, 33-60	4.9	33
168	Dyslipidemia in Patients with Kidney Disease. <i>Cardiology Clinics</i> , 2021 , 39, 353-363	2.5	1
167	Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. <i>Journal of Clinical Lipidology</i> , 2021 ,	4.9	6
166	JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 4-15	4.9	3
165	Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 88-97.e2	4.9	6
164	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 398-413	4.9	29
163	REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. <i>Circulation</i> , 2020 , 141, 367-375	16.7	67
162	Authors' response to letter by Anagnostis and Stevenson, "Is there a role for menopausal hormone therapy in a woman with increased lipoprotein(a) concentrations?". <i>Journal of Clinical Lipidology</i> , 2020 , 14, 156-157	4.9	

161	Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2791-2802	15.1	152
160	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 374-392	4.9	156
159	The Statin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 415-424	4.9	16
158	Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. <i>Circulation</i> , 2019 , 140, e673-e691	16.7	169
157	Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1159-1161	15.1	52
156	Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 586-593.e5	4.9	6
155	National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 860-872	4.9	49
154	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2019 , 380, 11-22	59.2	1316
153	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, e38-e81	9.4	231
152	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018 , 39, 2526-2539	9.5	156
151	Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 78-88	4.9	17
150	Safety and efficacy of statin therapy. <i>Nature Reviews Cardiology</i> , 2018 , 15, 757-769	14.8	131
149	Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. <i>Current Atherosclerosis Reports</i> , 2017 , 19, 29	6	11
148	The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 179-186	3.9	52
147	Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 880-890	4.9	73
146	Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 891-900	4.9	34
145	Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association. <i>Circulation</i> , 2017 , 135, e867-e884	16.7	371
144	Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. <i>Clinical Cardiology</i> , 2017 , 40, 138-148	3.3	114

143	Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ) . <i>Patient</i> , 2017 , 10, 321-334	3.7	9
142	Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins. <i>Evidence-Based Medicine</i> , 2017 , 22, 210		3
141	Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1680-1681	15.1	15
140	Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 833-841	4.9	51
139	Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 305-13	3.9	27
138	Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). <i>Surgery for Obesity and Related Diseases</i> , 2016 , 12, 468-495	3	36
137	New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk: A Comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016 , 45, 17-37	5.5	18
136	National Lipid Association Annual Summary of Clinical Lipidology 2016. <i>Journal of Clinical Lipidology</i> , 2016 , 10, S1-43	4.9	74
135	Effect of Pharmacist Counseling Intervention on Health Care Utilization Following Hospital Discharge: A Randomized Control Trial. <i>Journal of General Internal Medicine</i> , 2016 , 31, 470-7	4	42
134	Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 33-57	4.9	24
133	Beta-human Chorionic Gonadotropin-producing Renal Cell Carcinoma. <i>American Journal of Medicine</i> , 2016 , 129, e29-31	2.4	2
132	Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 15-32	4.9	13
131	Metabolic syndrome is associated with muscle symptoms among statin users. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1022-1029	4.9	12
130	National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <i>Journal of Clinical Lipidology</i> , 2015 , 9, 129-69	4.9	478
129	New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines with the 2014 National Lipid Association recommendations for patient-centered management of dyslipidemia. <i>Cardiology Clinics</i> , 2015 , 33, 181-96	2.5	20
128	The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1050-67	15.1	158
127	Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. <i>Journal of Clinical Lipidology</i> , 2015 , 9, 758-769	4.9	306
126	Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015 , 36, 1012-22	9.5	770

125	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015 , 9, S1-122.e1	4.9	293
124	Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia. <i>American Journal of Medicine</i> , 2014 , 127, 36-44.e1	2.4	48
123	National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. <i>Journal of Clinical Lipidology</i> , 2014 , 8, 473-88	4.9	323
122	An assessment by the Statin Muscle Safety Task Force: 2014 update. <i>Journal of Clinical Lipidology</i> , 2014 , 8, S58-71	4.9	300
121	NLA Task Force on Statin Safety--2014 update. <i>Journal of Clinical Lipidology</i> , 2014 , 8, S1-4	4.9	101
120	An assessment by the Statin Intolerance Panel: 2014 update. <i>Journal of Clinical Lipidology</i> , 2014 , 8, S72-81.9	4.9	107
119	Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. <i>Atherosclerosis</i> , 2014 , 235, 585-91	3.1	42
118	Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia. <i>Clinical Lipidology</i> , 2014 , 9, 149-161		4
117	Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. <i>Journal of Clinical Lipidology</i> , 2014 , 8, 554-561	4.9	110
116	National Lipid Association Annual Summary of Clinical Lipidology 2015. <i>Journal of Clinical Lipidology</i> , 2014 , 8, S1-36	4.9	56
115	Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study. <i>Journal of Clinical Lipidology</i> , 2014 , 8, 69-76	4.9	34
114	Low literacy is associated with uncontrolled blood pressure in primary care patients with hypertension and heart disease. <i>Patient Education and Counseling</i> , 2014 , 96, 165-70	3.1	43
113	Effect of health information technology interventions on lipid management in clinical practice: a systematic review of randomized controlled trials. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 546-60	4.9	24
112	Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis. <i>Evidence-Based Medicine</i> , 2013 , 18, 175-6		
111	Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 102-8	4.9	28
110	Lipoprotein(a), cardiovascular disease, and contemporary management. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 1294-311	6.4	74
109	Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 573-609	4.9	16
108	Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 472-83 ^{4.9}	4.9	170

107	Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 399-407	4.9	18
106	Achieving adherence to lipid-lowering regimens. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 4-13	4.9	1
105	Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin. <i>Current Medical Research and Opinion</i> , 2013 , 29, 773-81	2.5	2
104	Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 5-18	4.9	194
103	Hospital use and medical care costs up to 5 years after triglyceride lowering among patients with severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 443-9	4.9	8
102	Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 208-15	4.9	311
101	Authors' reply to commentary entitled EPA and DHA: Distinct yet essential n-3 fatty acids. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 477-479	4.9	2
100	Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 450-61	4.9	38
99	Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. <i>American Journal of Cardiology</i> , 2012 , 110, 1468-76	3	86
98	Improving Medication Adherence through Graphically Enhanced Interventions in Coronary Heart Disease (IMAGE-CHD): a randomized controlled trial. <i>Journal of General Internal Medicine</i> , 2012 , 27, 1609-17	4.7	48
97	A new pure E eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. <i>Expert Review of Cardiovascular Therapy</i> , 2012 , 10, 687-95	2.5	8
96	Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trial. <i>Annals of Internal Medicine</i> , 2012 , 157, 1-10	8	205
95	Opening a new lipid "apo-theary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. <i>Mayo Clinic Proceedings</i> , 2011 , 86, 762-80	6.4	25
94	Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 457-63	15.1	118
93	Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Low-Density Lipoprotein Cholesterol: A Critical Review. <i>Journal of Clinical Lipidology</i> , 2011 , 5, 200-201	4.9	4
92	Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011 , 5, 338-67	4.9	201
91	Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. <i>Current Atherosclerosis Reports</i> , 2011 , 13, 474-83	6	211
90	Estimating health and economic benefits from using prescription omega-3 fatty acids in patients with severe hypertriglyceridemia. <i>American Journal of Cardiology</i> , 2011 , 108, 691-7	3	11

89	Statin-induced myopathy: a review and update. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 373-87	4.1	194
88	Avoiding statin myopathy: understanding key drug interactions. <i>Clinical Lipidology</i> , 2011 , 6, 665-674		14
87	Development and evaluation of a medication counseling workshop for physicians: can we improve on 'take two pills and call me in the morning?'. <i>Medical Education Online</i> , 2011 , 16,	4.4	15
86	Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old. <i>Clinical Lipidology</i> , 2011 , 6, 131-136		4
85	Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety. <i>Clinical Lipidology</i> , 2010 , 5, 627-649		2
84	Rationale and design of the Pharmacist Intervention for Low Literacy in Cardiovascular Disease (PILL-CVD) study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010 , 3, 212-9	5.8	48
83	Using apolipoprotein B to manage dyslipidemic patients: time for a change?. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 440-5	6.4	45
82	A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 365-79	6.4	35
81	Using Apolipoprotein B to Manage DyslipidemiaReply□ <i>Mayo Clinic Proceedings</i> , 2010 , 85, 769-771	6.4	1
80	Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. <i>Clinical Cardiology</i> , 2010 , 33, 609-619	3.3	5
79	Association of age, health literacy, and medication management strategies with cardiovascular medication adherence. <i>Patient Education and Counseling</i> , 2010 , 81, 177-81	3.1	93
78	Omega-3 Fatty acids for cardiovascular disease prevention. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010 , 12, 365-80	2.1	37
77	Therapeutic options to further lower C-reactive protein for patients on statin treatment. <i>Current Atherosclerosis Reports</i> , 2010 , 12, 34-42	6	13
76	Evidence-based management of statin myopathy. <i>Current Atherosclerosis Reports</i> , 2010 , 12, 322-30	6	60
75	30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. <i>American Journal of Cardiology</i> , 2010 , 106, 969-75	3	114
74	Health literacy and the quality of physician-patient communication during hospitalization. <i>Journal of Hospital Medicine</i> , 2010 , 5, 269-75	2.7	72
73	Continuing Medical Education Program in the Journal of Hospital Medicine. <i>Journal of Hospital Medicine</i> , 2010 , 5, 268-268	2.7	
72	Omega-3 Fatty Acids 2009 , 326-338		7

71	Inhaled anticholinergics and the long-term treatment of chronic obstructive pulmonary disease: Weighing benefits and risks. <i>Clinical Cornerstone</i> , 2009 , 9, 45-9		
70	Chronic kidney disease and statins: improving cardiovascular outcomes. <i>Current Atherosclerosis Reports</i> , 2009 , 11, 301-8	6	8
69	Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. <i>Value in Health</i> , 2009 , 12, 118-23	3.3	189
68	Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 316-22	15.1	280
67	Myopathy with statin-fibrate combination therapy: clinical considerations. <i>Nature Reviews Endocrinology</i> , 2009 , 5, 507-18	15.2	60
66	Effect of baseline plasma fatty acids on eicosapentaenoic acid levels in individuals supplemented with alpha-linolenic acid. <i>International Journal of Food Sciences and Nutrition</i> , 2009 , 60 Suppl 5, 28-37	3.7	1
65	Managing dyslipidemia in chronic kidney disease. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 2375-84	15.1	132
64	The importance of non-HDL cholesterol reporting in lipid management. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 267-73	4.9	111
63	Effects of niacin on glucose control in patients with dyslipidemia. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 470-84	6.4	83
62	Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 687-700	6.4	54
61	Medication use among inner-city patients after hospital discharge: patient-reported barriers and solutions. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 529-35	6.4	66
60	Fluvastatin, rhabdomyolysis, and myotoxicity. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 1296; author reply 1297	6.4	2
59	Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 1316-1325	6.4	21
58	Fluvastatin, Rhabdomyolysis, and Myotoxicity Reply <i>Mayo Clinic Proceedings</i> , 2008 , 83, 1297	6.4	3
57	Clinical characterization and molecular mechanisms of statin myopathy. <i>Expert Review of Cardiovascular Therapy</i> , 2008 , 6, 955-69	2.5	41
56	Medication Use Among Inner-City Patients After Hospital Discharge: Patient-Reported Barriers and Solutions. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 529-535	6.4	108
55	Toward Pain-Free Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 687-700	6.4	127
54	Initiating statins in the elderly: the evolving challenge. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2008 , 15, 182-7	4	7

53	Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. <i>American Journal of Clinical Nutrition</i> , 2008 , 87, 1981S-90S	7	108
52	Clinical research in low-literacy populations: using teach-back to assess comprehension of informed consent and privacy information. <i>IRB: Ethics & Human Research</i> , 2008 , 30, 13-9		70
51	Safety considerations with fibrate therapy. <i>American Journal of Cardiology</i> , 2007 , 99, 3C-18C	3	279
50	Safety considerations with gastrointestinally active lipid-lowering drugs. <i>American Journal of Cardiology</i> , 2007 , 99, 47C-55C	3	65
49	Beyond lipids: the role of omega-3 fatty acids from fish oil in the prevention of coronary heart disease. <i>Current Atherosclerosis Reports</i> , 2007 , 9, 145-53	6	28
48	Patient literacy and question-asking behavior during the medical encounter: a mixed-methods analysis. <i>Journal of General Internal Medicine</i> , 2007 , 22, 782-6	4	199
47	Development of an illustrated medication schedule as a low-literacy patient education tool. <i>Patient Education and Counseling</i> , 2007 , 66, 368-77	3.1	145
46	Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. <i>Journal of Nursing Measurement</i> , 2007 , 15, 203-19	0.5	142
45	The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. <i>Current Opinion in Lipidology</i> , 2007 , 18, 401-8	4.4	167
44	Low-literacy interventions to promote discussion of prostate cancer: a randomized controlled trial. <i>American Journal of Preventive Medicine</i> , 2007 , 33, 83-90	6.1	36
43	Hypertriglyceridemia and cardiovascular risk reduction. <i>Clinical Therapeutics</i> , 2007 , 29, 763-777	3.5	97
42	Quality of care in African-American patients admitted for congestive heart failure at a university teaching hospital. <i>American Journal of Cardiology</i> , 2006 , 97, 690-3	3	12
41	Statin safety: lessons from new drug applications for marketed statins. <i>American Journal of Cardiology</i> , 2006 , 97, 44C-51C	3	107
40	Statin safety: an assessment using an administrative claims database. <i>American Journal of Cardiology</i> , 2006 , 97, 61C-68C	3	97
39	Secondary prevention of coronary artery disease with omega-3 fatty acids. <i>American Journal of Cardiology</i> , 2006 , 98, 61i-70i	3	47
38	Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. <i>American Journal of Cardiology</i> , 2006 , 97, 89C-94C	3	310
37	Comparison of African-American patients with systolic heart failure versus preserved ejection fraction. <i>American Journal of Cardiology</i> , 2006 , 98, 806-8	3	11
36	Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study. <i>Current Medical Research and Opinion</i> , 2006 , 22, 1065-73	2.5	23

35	The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?. <i>Mayo Clinic Proceedings</i> , 2006 , 81, 1225-31	6.4	16
34	Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly. <i>Drug Safety</i> , 2006 , 29, 421-48	5.1	38
33	Fibrates in combination with statins in the management of dyslipidemia. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 35-41; quiz 42-3	2.3	40
32	Flaxseed oil increases the plasma concentrations of cardioprotective (n-3) fatty acids in humans. <i>Journal of Nutrition</i> , 2006 , 136, 83-7	4.1	147
31	Development and Implementation of a Health Literacy Training Program for Medical Residents. <i>Medical Education Online</i> , 2006 , 11, 4612	4.4	26
30	Predictors of medication self-management skill in a low-literacy population. <i>Journal of General Internal Medicine</i> , 2006 , 21, 852-6	4	162
29	Usefulness of omega-3 fatty acids and the prevention of coronary heart disease. <i>American Journal of Cardiology</i> , 2005 , 96, 1521-9	3	115
28	Identifying and assisting low-literacy patients with medication use: a survey of community pharmacies. <i>Annals of Pharmacotherapy</i> , 2005 , 39, 1441-5	2.9	56
27	Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention. <i>Annals of Pharmacotherapy</i> , 2005 , 39, 610-6	2.9	7
26	Effects of race on lipid-lowering management in hospitalized patients with coronary heart disease. <i>American Journal of Cardiology</i> , 2004 , 93, 1167-70	3	5
25	Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. <i>American Journal of Cardiology</i> , 2004 , 94, 1140-6 ³		196
24	Fluvastatin: clinical and safety profile. <i>Drugs</i> , 2004 , 64, 1305-23	12.1	19
23	Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. <i>Expert Opinion on Drug Safety</i> , 2003 , 2, 269-86	4.1	15
22	Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. <i>American Journal of Cardiology</i> , 2003 , 91, 1134-6	3	5
21	Risk for myopathy with statin therapy in high-risk patients. <i>Archives of Internal Medicine</i> , 2003 , 163, 553-64		338
20	An assessment of obesity among African-American women in an inner city primary care clinic. <i>Journal of the National Medical Association</i> , 2002 , 94, 1049-57	2.3	9
19	Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. <i>Current Atherosclerosis Reports</i> , 2001 , 3, 373-82	6	23
18	The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. <i>Archives of Internal Medicine</i> , 2001 , 161, 2185-92		145

17	Reaching National Cholesterol Education Program Goals: a managed care approach to improving hyperlipidemia disease management outcomes. Introduction. <i>American Journal of Medicine</i> , 2001 , 110 Suppl 6A, 1S-2S	2.4	39
16	Clinical context: current concepts of coronary heart disease management. <i>American Journal of Medicine</i> , 2001 , 110 Suppl 6A, 3S-11S	2.4	28
15	Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. <i>Archives of Internal Medicine</i> , 2000 , 160, 1361-9		60
14	Use of a low-literacy patient education tool to enhance pneumococcal vaccination rates. A randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 1999 , 282, 646-50	27.4	107
13	New perspectives on the management of low levels of high-density lipoprotein cholesterol. <i>Archives of Internal Medicine</i> , 1999 , 159, 1049-57		49
12	Maximizing the cost-effectiveness of lipid-lowering therapy. <i>Archives of Internal Medicine</i> , 1998 , 158, 1977-89		54
11	Improving the Cost Effectiveness of Lipid Lowering Therapy in Coronary Heart Disease Prevention. <i>Medical Science Symposia Series</i> , 1998 , 275-284		
10	Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease. <i>Current Opinion in Lipidology</i> , 1997 , 8, 369-74	4.4	11
9	Changes in plasma cholesterol levels after hospitalization for acute coronary events. <i>Cardiology</i> , 1996 , 87, 194-9	1.6	22
8	Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. <i>American Journal of Cardiology</i> , 1996 , 78, 32-41	3	19
7	Efficacy and Safety of Pravastatin in African Americans With Primary Hypercholesterolemia. <i>Archives of Internal Medicine</i> , 1995 , 155, 1900		20
6	Fluvastatin with and without niacin for hypercholesterolemia. <i>American Journal of Cardiology</i> , 1994 , 74, 149-54	3	79
5	Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. <i>American Journal of Cardiology</i> , 1994 , 73, 25D-29D	3	23
4	Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy. <i>American Journal of Medicine</i> , 1994 , 96, 64S-68S	2.4	12
3	Long-term treatment of hypercholesterolemia with dietary fiber. <i>American Journal of Medicine</i> , 1994 , 97, 504-8	2.4	45
2	Formulary policy for cholesterol reduction. <i>Journal of General Internal Medicine</i> , 1991 , 6, 266-7	4	
1	Quitting smoking: nicotine vs placebo gum. <i>JAMA - Journal of the American Medical Association</i> , 1989 , 262, 773-4	27.4	